Royal Bank of Canada
BRNS

Royal Bank of Canada’s Barinthus Biotherapeutics BRNS Stock Holding History

Royal Bank of Canada’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-105
Closed – – 7039
2025
Q1 		$0 Buy
+105
New +$108 ﹤0.01% 6831
2024
Q3 		– Sell
-4,065
Closed -$6K – 6877
2024
Q2 		$6K Buy
+4,065
New +$9.18K ﹤0.01% 6476
2023
Q4 		– Sell
-1,000
Closed -$3K – 7134
2023
Q3 		$3K Buy
+1,000
New +$2.15K ﹤0.01% 6706

Other funds holding BRNS

MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Royal Bank of Canada's BRNS Position: Q2 2025 in Review

Royal Bank of Canada sold out of Barinthus Biotherapeutics (BRNS) in Q2 2025, closing a stake of 105 shares.

Royal Bank of Canada first reported a position in BRNS in Q3 2023 and held it in 3 quarters. The position peaked at $6K in Q2 2024. 14 funds tracked by Wall St. Rank hold BRNS as of Q2 2025.

  • Royal Bank of Canada reported no remaining Barinthus Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Royal Bank of Canada sold 105 Barinthus Biotherapeutics shares in Q2 2025.
  • Royal Bank of Canada first reported a position in Barinthus Biotherapeutics in Q3 2023 and held it in 3 quarters.
  • Royal Bank of Canada's Barinthus Biotherapeutics position peaked at $6K in Q2 2024.
  • 14 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q2 2025.

Based on Royal Bank of Canada's 13F filing for Q2 2025, filed 14 Aug 2025.